Dr. Gregory Harriman 

Dr. Gregory Harriman is an accomplished physician, scientist and biomedical executive having over 25 years of experience with increasing responsibilities in academic medicine and the biopharmaceutical industry. In previous positions at IVAX, Centocor and J&J, he led clinical R&D groups responsible for development of both drugs and biologics, including Remicade® (infliximab). 

Dr. Harriman founded Main Line Ventures, an investment and consultancy company focused on life sciences opportunities and was also a member of Robin Hood Ventures. He is currently on the Board of Directors of the BioAdvance portfolio companies, Opsidio, Ribonova and Treventis, and was previously a Board member for Novira, Immunome, GenPro and Annovis. 

He attended the University of California, Berkeley as an undergraduate and received his medical degree at the University of California, San Diego. He trained in internal medicine at Barnes Hospital and completed a fellowship in infectious diseases at the NIH. He is board-certified in internal medicine, infectious diseases and clinical & laboratory immunology. He had a successful academic career at the NIH and Baylor College of Medicine, publishing over 40 scientific papers.